AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialAbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral Share XAbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trialhttps://pharmaphorum.com/news/abbvie-preps-filings-after-abbv-951-tops-oral-parkinsons-drugs-in-trial/
